Cite
HARVARD Citation
Hirata, S. et al. (n.d.). FRI0097 Baseline Serum 14-3-3 ETA Independently Predicts Clinically Important Improvements in HAQ-DI in Patients with Rheumatoid Arthritis Treated with Tocilizumab. Annals of the rheumatic diseases. pp. 462-463. [Online].